Articles for author: Russ Cohen

Russ Cohen

Netflix: From Streaming Pioneer to Entertainment Innovator Netflix: From Streaming Pioneer to Entertainment Innovator

Netflix (NASDAQ: NFLX) completely revolutionized the way content is consumed. Initially a DVD rental service, Netflix swiftly shifted gears to embrace the streaming era. Competing media giants like The Walt Disney Company, Warner Bros. Discovery, and Amazon have entered the streaming arena vying to emulate Netflix’s success. Netflix Dives into Live Entertainment Gone are the ...

Russ Cohen

Ford Motor: A Diamond in the Rough for Dividend Investors Ford Motor: A Diamond in the Rough for Dividend Investors

Undoubtedly, Ford Motor’s formidable reputation in the automobile industry is as well-known as Henry Ford is to the very history of American innovation. Founded way back in 1903, this stalwart from Dearborn, Michigan, stands tall as one of Detroit’s famous “Big Three,” a global titan in vehicle design, manufacturing, and service. With iconic brands like ...

Russ Cohen

Pure Storage Broker Recommendations Analysis Deciphering Broker Recommendations: A Deep Dive into Pure Storage (PSTG)

When contemplating stock investments, the sway of analyst recommendations cannot be underestimated. These pronouncements from brokerage analysts extensively impact stock prices, yet the question lingers – how pivotal are they truly? Before examining the credibility of brokerage endorsements and methods to leverage them judiciously, let’s delve into the sentiments of Wall Street titans regarding Pure ...

Russ Cohen

Is It Worth Investing in Alibaba (BABA) Based on Wall Street's Bullish Views?

Unveiling the Facade: Alibaba (BABA) on Wall Street’s Radar The Allure of Wall Street Recommendations Often regarded as gospel, the pronouncements of Wall Street analysts wield significant influence over investors, dictating buy, sell, or hold decisions. Yet, do these Wall Street sages truly hold the key to successful investments? Deciphering Alibaba’s Standing Before delving into ...

Russ Cohen

Larimar Therapeutics: A Resilient Rise After FDA Removal of Clinical Hold The Triumph of Larimar Therapeutics Amid FDA Regulatory Shift

Iryna Drozd Larimar Therapeutics’ stock, listed under NASDAQ as LRMR, soared by an impressive 24% during after-hours trading on Monday. This surge was triggered by the exhilarating news that the FDA had lifted a partial clinical hold on Larimar’s nomlabofusp clinical program following a meticulous assessment of Phase 2 data pertaining to the drug. Among ...